FCOMV
THRX

Foresite Capital Opportunity Management V’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$5.56M Hold
959,275
– – 16.71% 2
2022
Q2 		$5.3M Buy
959,275
+490,455
+105% +$4.05M 13.37% 2
2022
Q1 		$5.41M Hold
468,820
– – 7.57% 3
2021
Q4 		$5.95M Buy
+468,820
New +$7.08M 3.99% 5

Other funds holding THRX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Foresite Capital Opportunity Management V's THRX Position: Q3 2022 in Review

Foresite Capital Opportunity Management V held its Theseus Pharmaceuticals, Inc. Common Stock (THRX) position steady in Q3 2022 at 959,275 shares worth $5.56M. The position accounts for 16.71% of the portfolio, ranked #2.

Foresite Capital Opportunity Management V first reported a position in THRX in Q4 2021 and has held it in 4 quarters since. The position peaked at $5.95M in Q4 2021. 51 funds tracked by Wall St. Rank hold THRX as of Q3 2022.

  • Foresite Capital Opportunity Management V held 959,275 shares of Theseus Pharmaceuticals, Inc. Common Stock worth $5.56M as of Q3 2022.
  • Foresite Capital Opportunity Management V left its Theseus Pharmaceuticals, Inc. Common Stock share count unchanged in Q3 2022.
  • Theseus Pharmaceuticals, Inc. Common Stock made up 16.71% of Foresite Capital Opportunity Management V's portfolio in Q3 2022, its #2 holding.
  • Foresite Capital Opportunity Management V first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and has held it in 4 quarters since.
  • Foresite Capital Opportunity Management V's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $5.95M in Q4 2021.
  • 51 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q3 2022, filed 14 Nov 2022.